{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:19:17Z","timestamp":1787771957053,"version":"build-2784847793"},"reference-count":33,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000190","name":"University of Alberta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["RGPIN-2020-04046"],"award-info":[{"award-number":["RGPIN-2020-04046"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.dmd.2025.100203","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T09:13:43Z","timestamp":1763630023000},"page":"100203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Characterization of genetically modified human embryonic kidney 293 cells lacking equilibrative nucleoside transporter subtype 2, or both subtypes 1 and 2, and the impact of their loss on sensitivity to chemotherapeutic purine\/pyrimidine analogs"],"prefix":"10.1016","volume":"53","author":[{"given":"Nayiar","family":"Shahid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9006-7529","authenticated-orcid":false,"given":"James R.","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmd.2025.100203_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115741","article-title":"Nucleoside-based anticancer drugs: mechanism of action and drug resistance","volume":"215","author":"Hruba","year":"2023","journal-title":"Biochem Pharmacol"},{"issue":"47","key":"10.1016\/j.dmd.2025.100203_bib2","doi-asserted-by":"crossref","first-page":"7524","DOI":"10.1038\/sj.onc.1206952","article-title":"Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy","volume":"22","author":"Damaraju","year":"2003","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.dmd.2025.100203_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10555-007-9044-4","article-title":"The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs","volume":"26","author":"Zhang","year":"2007","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"10.1016\/j.dmd.2025.100203_bib4","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3390\/pharmaceutics15020364","article-title":"The role of solute carrier transporters in efficient anticancer drug delivery and therapy","volume":"15","author":"Puris","year":"2023","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.dmd.2025.100203_bib5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1368-7646(98)80047-2","article-title":"Nucleoside transport and its significance for anticancer drug resistance","volume":"1","author":"Mackey","year":"1998","journal-title":"Drug Resist Updat"},{"issue":"1","key":"10.1016\/j.dmd.2025.100203_bib6","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1124\/mol.105.015768","article-title":"A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems","volume":"69","author":"King","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.dmd.2025.100203_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fphar.2015.00013","article-title":"Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets","volume":"6","author":"Pastor-Anglada","year":"2015","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2025.100203_bib8","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1349-7006.2010.01837.x","article-title":"Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd)","volume":"102","author":"Nishio","year":"2011","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1016\/j.dmd.2025.100203_bib9","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00280-012-2054-0","article-title":"Investigating the role of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapy","volume":"71","author":"Phua","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2025.100203_bib10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.dmpk.2016.12.001","article-title":"Contribution of equilibrative nucleoside transporter (ENT) 2 to fluorouracil transport in rat placental trophoblast cells","volume":"32","author":"Takagi","year":"2017","journal-title":"Drug Metab Pharmacokinet"},{"issue":"5","key":"10.1016\/j.dmd.2025.100203_bib11","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3892\/etm.2023.11911","article-title":"Increased ENT2 expression and its association with altered purine metabolism in cell lines derived from different stages of colorectal cancer","volume":"25","author":"Naes","year":"2023","journal-title":"Exp Ther Med"},{"issue":"10","key":"10.1016\/j.dmd.2025.100203_bib12","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1124\/dmd.124.001814","article-title":"Development of a novel HEK293 cell model lacking SLC29A1 to study the pharmacology of endogenous SLC29A2-encoded equilibrative nucleoside transporter subtype 2","volume":"52","author":"Shahid","year":"2024","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2025.100203_bib13","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/s41467-018-03927-0","article-title":"Incorporation of bridged nucleic acids into CRISPR RNAs improves Cas9 endonuclease specificity","volume":"9","author":"Cromwell","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.dmd.2025.100203_bib33","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"issue":"18","key":"10.1016\/j.dmd.2025.100203_bib14","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1016\/0006-2952(85)90340-5","article-title":"2-Chloroadenosine, a permeant for the nucleoside transporter","volume":"34","author":"Jarvis","year":"1985","journal-title":"Biochem Pharmacol"},{"issue":"pt 2","key":"10.1016\/j.dmd.2025.100203_bib15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1042\/BJ20041571","article-title":"Subtype-specific regulation of equilibrative nucleoside transporters by protein kinase CK2","volume":"386","author":"Stolk","year":"2005","journal-title":"Biochem J"},{"issue":"23","key":"10.1016\/j.dmd.2025.100203_bib16","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"10.1016\/j.dmd.2025.100203_bib17","doi-asserted-by":"crossref","first-page":"8375","DOI":"10.1074\/jbc.275.12.8375","volume":"275","author":"Ward","year":"2000","journal-title":"J Biol Chem"},{"issue":"pt 3","key":"10.1016\/j.dmd.2025.100203_bib18","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1042\/bj3280739","article-title":"Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta","volume":"328","author":"Griffiths","year":"1997","journal-title":"Biochem J"},{"issue":"6","key":"10.1016\/j.dmd.2025.100203_bib19","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1124\/mol.118.114389","article-title":"Characterization of 6-mercaptopurine transport by the SLC43A3-encoded nucleobase transporter","volume":"95","author":"Ruel","year":"2019","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100203_bib20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/15257770.2016.1210805","article-title":"Equilibrative nucleoside transporters\u2014a review","volume":"36","author":"Boswell-Casteel","year":"2017","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"pt 2","key":"10.1016\/j.dmd.2025.100203_bib21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1042\/bj2870431","article-title":"Differential uptake of [3H]guanosine by nucleoside transporter subtypes in Ehrlich ascites tumour cells","volume":"287","author":"Hammond","year":"1992","journal-title":"Biochem J"},{"issue":"10","key":"10.1016\/j.dmd.2025.100203_bib22","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1177\/2472555219870123","article-title":"Current progress on equilibrative nucleoside transporter function and inhibitor design","volume":"24","author":"Rehan","year":"2019","journal-title":"SLAS Discov"},{"issue":"24","key":"10.1016\/j.dmd.2025.100203_bib23","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1016\/j.bmcl.2014.10.026","article-title":"Dilazep analogues for the study of equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2)","volume":"24","author":"Playa","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"10.1016\/j.dmd.2025.100203_bib24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1124\/molpharm.120.000169","article-title":"Predicting drug interactions with human equilibrative nucleoside transporters 1 and 2 using functional knockout cell lines and bayesian modeling","volume":"99","author":"Miller","year":"2021","journal-title":"Mol Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2025.100203_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115686","article-title":"Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes","volume":"10","author":"Focaccetti","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.dmd.2025.100203_bib26","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood.V62.4.737.737","article-title":"Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes","volume":"62","author":"Carson","year":"1983","journal-title":"Blood"},{"key":"10.1016\/j.dmd.2025.100203_bib27","series-title":"Purine Metabolism in Man-IV: Part B: Biochemical, Immunological, and Cancer Research","first-page":"351","article-title":"Cell cycle independent lymphocytotoxicity of 2-chlorodeoxyadenosine","author":"Carson","year":"1984"},{"issue":"3","key":"10.1016\/j.dmd.2025.100203_bib28","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/bjc.1991.327","article-title":"Nucleoside salvage and resistance to antimetabolite anticancer agents","volume":"64","author":"Fox","year":"1991","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.dmd.2025.100203_bib29","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3390\/cells11040739","article-title":"Re-discovery of pyrimidine salvage as target in cancer therapy","volume":"11","author":"Walter","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.dmd.2025.100203_bib30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","article-title":"Cladribine: mode of action and implications for treatment of multiple sclerosis","volume":"34","author":"Leist","year":"2011","journal-title":"Clin Neuropharmacol"},{"issue":"23","key":"10.1016\/j.dmd.2025.100203_bib31","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1007\/s00018-016-2288-9","article-title":"Novel nuclear hENT2 isoforms regulate cell cycle progression via controlling nucleoside transport and nuclear reservoir","volume":"73","author":"Gra\u00f1\u00e9-Boladeras","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.dmd.2025.100203_bib32","first-page":"27","article-title":"Impact of genetic variants in the solute carrier (SLC) genes encoding drug uptake transporters on the response to anticancer chemotherapy","volume":"7","author":"Marin","year":"2024","journal-title":"Cancer Drug Resist"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625095121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625095121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T11:58:45Z","timestamp":1773921525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625095121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0090955625095121"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100203","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of genetically modified human embryonic kidney 293 cells lacking equilibrative nucleoside transporter subtype 2, or both subtypes 1 and 2, and the impact of their loss on sensitivity to chemotherapeutic purine\/pyrimidine analogs","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100203","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100203"}}